Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/9949
Title: Effectiveness and safety of cabazitaxel chemotherapy for metastatic castration-resistant prostatic carcinoma on Turkish patients (The Anatolian Society of Medical Oncology)
Authors: Süner, A.
Aydin, D.
Hacioglu, M.B.
Dogu, Gököz Gamze
Imamoglu, G.I.
Menekşe, S.
Pilanci, K.N.
Keywords: Cabazitaxel
Chemotherapy
Prostate cancer
Toxicities
antiandrogen
cabazitaxel
docetaxel
granulocyte colony stimulating factor
prednisolone
antineoplastic agent
taxoid
adult
aged
anemia
anorexia
Article
cancer center
cancer chemotherapy
cancer control
cancer diagnosis
cancer growth
cancer patient
cancer survival
castration resistant prostate cancer
controlled study
diarrhea
disease severity
drug dose reduction
drug efficacy
drug fatality
drug safety
fatigue
febrile neutropenia
human
human tissue
major clinical study
male
medical society
metastasis potential
nausea
neutropenia
orchiectomy
overall survival
peripheral neuropathy
progression free survival
prostate adenocarcinoma
retrospective study
survival time
thrombocytopenia
treatment response
Turk (people)
vomiting
clinical trial
disease free survival
epidemiology
metastasis
middle aged
mortality
multicenter study
pathology
Prostatic Neoplasms, Castration-Resistant
treatment outcome
Turkey
very elderly
Adult
Aged
Aged, 80 and over
Antineoplastic Agents
Disease-Free Survival
Humans
Male
Middle Aged
Neoplasm Metastasis
Retrospective Studies
Taxoids
Treatment Outcome
Publisher: Verduci Editore
Abstract: OBJECTIVE: Prostate cancer is among the most common cancers in males. Prostate cancer is androgen dependent in the beginning, but as time progresses, it becomes refractory to androgen deprivation treatment. At this stage, docetaxel has been used as standard treatment for years. Cabazitaxel has become the first chemotherapeutic agent which has been shown to increase survival for patients with metastatic Castrate Resistant Prostate Cancer (mCRPC) that progresses after docetaxel. Phase 3 TROPIC study demonstrated that cabazitaxel prolongs survival. PATIENTS AND METHODS: In this study, we evaluated a total of 103 patients who took cabaz-itaxel chemotherapy for mCRPC diagnosis in 21 centers of Turkey, retrospectively. This study included patients who progressed despite doc-etaxel treatments, had ECOG performance score between 0-2, and used cabazitaxel treatment. Patients received cabazitaxel 25 mg/m2 at every 3 weeks, and prednisolone 5 mg twice a day. RESULTS: Median number of cabazitaxel cures was 5.03 (range: 1-17). Cabazitaxel response evaluation detected that 34% of the patients had a partial response, 22.3% had stable disease and 32% had a progressive disease. Grade 3-4 hema-tological toxicities were neutropenia (28.2%), neutropenic fever (14.5%), anemia (6.7%), and thrombocytopenia (3.8%). In our study, median progression-free survival (PFS) was 7.7 months and overall survival (OS) was 10.6 months. CONCLUSIONS: This study reflects toxicity profile of Turkish patients as a Caucasian race. We suggest that cabazitaxel is a safe and effective treatment option for mCRPC patients who progress after docetaxel. Moreover, ethnicity may play important roles both in treatment response and in toxicity profile.
URI: https://hdl.handle.net/11499/9949
ISSN: 1128-3602
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Show full item record



CORE Recommender

SCOPUSTM   
Citations

4
checked on Nov 23, 2024

WEB OF SCIENCETM
Citations

4
checked on Nov 22, 2024

Page view(s)

32
checked on Aug 24, 2024

Google ScholarTM

Check





Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.